E 21R

Drug Profile

E 21R

Alternative Names: E21R

Latest Information Update: 19 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanson Centre for Cancer Research
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 01 Sep 2003 E 21R is available for licensing (http://www.bresagen.com.au)
  • 11 Apr 2003 BresaGen has begun discussions with a major pharmaceutical company for collaborative development of E 21R
  • 11 Apr 2003 Discontinued - Phase-II for Chronic myelomonocytic leukaemia in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top